Towards Healthcare

Point of Care Infectious Disease Testing Companies and Corporate Growth

Date : 06 October 2025

Top Companies in the Market

Point of Care Infectious Disease Testing Market Companies

Market Forecast

The global point of care infectious disease testing market size is calculated at US$ 11.9 billion in 2024, grew to US$ 12.42 billion in 2025, and is projected to reach around US$ 17.75 billion by 2034. The market is expanding at a CAGR of 4.34% between 2025 and 2034.

  • Growing awareness: There is a rise in health awareness, which is increasing the use of POC infectious disease testing. Moreover, government initiatives are also promoting their use. At the same time, the government funding and investments from the private sector are accelerating their development as well as adoption rates.
  • Increasing home testing: For the early and effective diagnosis of infectious diseases, there is a growth in the demand for home testing devices, which is driving the point-of-care infectious disease testing market. Due to their enhanced access and accurate results, they are increasing patient convenience. This, in turn, is driving their innovations as well as collaborations among the companies.

For instance,

  • In June 2025, to accelerate research and development in the infectious disease testing field, a collaboration between Fujirebio, which is a leading innovator in in-vitro diagnostics, and Stanford Medicine was announced. Single-molecule counting technology developed by Fluxus, Inc., which is a Silicon Valley wholly-owned subsidiary of Fujirebio, will be used in the development of ultrasensitive immunoassays, where its adoption will be enhanced by this collaboration.

Market Value Chain Analysis

R&D

The R&D of the point-of-care infectious disease testing focuses on the development of accurate, portable, and rapid diagnostic devices and their integration with digital health tools, biosensors, and microfluidic platforms.

Key Players: F. Hoffmann-La Roche Ltd, Siemens Healthineers, Abbott, Danaher Corporation, Thermo Fisher Scientific Inc.

Clinical Trials and Regulatory Approvals

The analytical and clinical validity are evaluated in the clinical trials of point-of-care infectious disease testing, while the performance, risk assessments, and safety are the focus for their regulatory approvals.

Key Players: F. Hoffmann-La Roche Ltd, Abbott, Danaher Corporation, bioMérieux SA, QIAGEN N.V., QuidelOrtho Corporation

Formulation and Final Dosage Preparation

The integration and stabilization of the reagents on the strips or within a closed cartridge are included in the point-of-care infectious disease formulation, while the application of the sample on the device to trigger the reaction is involved in their final dosage preparation.

Key Players: F. Hoffmann-La Roche Ltd, Abbott, Danaher Corporation, Thermo Fisher Scientific Inc., QIAGEN N.V.

Patient Support and Services

The patient support and services of the point-of-care infectious disease testing focus on providing services such as integration with the telemedicine platforms, and guidance for the use of the device, specifically while home testing.

Key Players: Abbott, Danaher Corporation, Upfront Healthcare, OSP Labs, Portea Medical, and Itransition.

What is the Latest Announcement by the Industry Leader in the Market?

In July 2025, after announcing the investment in Principle Diagnostics, the new Chairman and CEO of Aqueous Health, Dan Eckert, stated that, by joining with Dr. Zyller and the Principal team for providing predictive diagnostic testing and services to a wide range of populations, they were delighted. They believe there is a rise in opportunity in the decentralized diagnostic testing market after the COVID-19 pandemic, positioning Aqueous Health to capitalize on the market. Therefore, with this collaboration, they are confident that they will be the industry leader in the diagnostics services and solutions.

Recent Developments in the Market

  • In April 2025, a new handheld, compact, smartphone-sized, battery-powered, and cost-effective diagnostic device, utilizing a lab-in-tube assay (LIT) technology, was developed by the researchers of Tulane University. It uses saliva samples for the detection of Mycobacterium tuberculosis (Mtb) DNA, making it the first of its kind.
  • In April 2025, at the ESCMID Global Congress 2025 held in Vienna, the Autolab™ HBH system was launched by the Autonomous Medical Devices Incorporated (AMDI). This system will be widely used for research and diagnostic purposes as it accelerates and simplifies molecular workflows.

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com